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We appreciate the letter from Dr. Oh, a leader in the treatment of Lambert-Eaton myasthenia 
(LEM). 
DAPPER was a multicenter, monitored, randomized controlled trial of 3,4-diaminopyridine base 
(3,4-DAP) in LEM, using an objective primary outcome measure that assesses dysfunction 
characteristic of LEM.
1
  All but one of the previous trials of 3,4-DAP in LEM were unmonitored 
single-center studies.
2-5
  The 2016 study of 3,4-diaminopyridine phosphate used a composite 
outcome measure that included the quantitative myasthenia gravis QMG score and a subjective, 
patient-derived assessment.
6
  Although the QMG of patients treated with 3,4-DAP showed 
marginally significant improvement in that study (p=0.045), the mean difference in QMG was 
only 1.7 points, which is not considered clinically significant in myasthenia gravis (MG).
7
 The 
clinical significance of change in QMG score has not been determined for LEM.  
Use of the QMG is problematic in LEM, in which strength typically facilitates, and thus may 
improve during testing.  Also, ocular and bulbar muscle functions, which are frequently normal 
in LEM, are major components of the QMG. In 2 previous trials of 3,4-DAP in LEM, the mean 
QMG improved 2.25 and 2.65 points, respectively, in patients receiving 3,4-DAP compared to 
those receiving placebo:
3,4
 Meta-analysis of these studies showed a mean advantage of 2.44 
QMG points of 3,4-DAP over placebo.
8
  Because of the poor performance of the QMG in these 
previous studies, DAPPER used the Triple Timed-Up-and-Go (3TUG) test, an outcome measure 
that assesses typical LEM dysfunction.
9
  To accommodate fatigue or facilitation, the 3TUG 
involves 3 repetitions of the timed-up-and-go test, which has been validated in the elderly
10,11
 
and patients with Parkinson Disease.
12,13
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The highly significant 3TUG results (p<0.0001) of DAPPER were corroborated by highly 
significant improvement in patient self-assessment of weakness and by changes in compound 
muscle action potential amplitudes. 
Studies are in progress to validate the 3TUG as a clinical measure in LEM.  
 
 
 
Acronyms: 3,4-DAP – 3,4-diaminopyridine; 3TUG – triple timed up-and-go-test; DAPPER -- 
3,4-DAP Product Efficacy Research; LEM – Lambert-Eaton myasthenia; MG – myasthenia 
gravis; QMG – quantitative myasthenia gravis score 
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